213 related articles for article (PubMed ID: 9129015)
1. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.
Hsu FJ; Caspar CB; Czerwinski D; Kwak LW; Liles TM; Syrengelas A; Taidi-Laskowski B; Levy R
Blood; 1997 May; 89(9):3129-35. PubMed ID: 9129015
[TBL] [Abstract][Full Text] [Related]
2. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
Davis TA; Hsu FJ; Caspar CB; van Beckhoven A; Czerwinsk DK; Liles TM; Taidi B; Benike CJ; Engleman EG; Levy R
Biol Blood Marrow Transplant; 2001; 7(9):517-22. PubMed ID: 11669219
[TBL] [Abstract][Full Text] [Related]
3. Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma.
Navarrete MA; Heining-Mikesch K; Schüler F; Bertinetti-Lapatki C; Ihorst G; Keppler-Hafkemeyer A; Dölken G; Veelken H
Blood; 2011 Feb; 117(5):1483-91. PubMed ID: 21045197
[TBL] [Abstract][Full Text] [Related]
4. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
[TBL] [Abstract][Full Text] [Related]
6. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
[TBL] [Abstract][Full Text] [Related]
7. Translational development of vaccination strategies in follicular NHL.
Sakamaki I; Qin H; Kwak LW
Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic lymphoma vaccines: importance of T-cell immunity.
Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
[TBL] [Abstract][Full Text] [Related]
9. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
Kwak LW; Campbell MJ; Czerwinski DK; Hart S; Miller RA; Levy R
N Engl J Med; 1992 Oct; 327(17):1209-15. PubMed ID: 1406793
[TBL] [Abstract][Full Text] [Related]
10. Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma.
Koumarianou A; Kountourakis P; Economopoulos T
J Steroid Biochem Mol Biol; 2008 Apr; 109(3-5):230-2. PubMed ID: 18406604
[TBL] [Abstract][Full Text] [Related]
11. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.
McCormick AA; Reddy S; Reinl SJ; Cameron TI; Czerwinkski DK; Vojdani F; Hanley KM; Garger SJ; White EL; Novak J; Barrett J; Holtz RB; Tusé D; Levy R
Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10131-6. PubMed ID: 18645180
[TBL] [Abstract][Full Text] [Related]
12. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
Neeson P; Pan ZK; Paterson Y
Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
Schuster SJ; Neelapu SS; Gause BL; Janik JE; Muggia FM; Gockerman JP; Winter JN; Flowers CR; Nikcevich DA; Sotomayor EM; McGaughey DS; Jaffe ES; Chong EA; Reynolds CW; Berry DA; Santos CF; Popa MA; McCord AM; Kwak LW
J Clin Oncol; 2011 Jul; 29(20):2787-94. PubMed ID: 21632504
[TBL] [Abstract][Full Text] [Related]
15. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
Hurvitz SA; Timmerman JM
Expert Opin Biol Ther; 2005 Jun; 5(6):841-52. PubMed ID: 15952914
[TBL] [Abstract][Full Text] [Related]
16. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations.
Caspar CB; Levy S; Levy R
Blood; 1997 Nov; 90(9):3699-706. PubMed ID: 9345055
[TBL] [Abstract][Full Text] [Related]
17. Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness.
Ashour AK; Petersen JL; McIlhaney MM; Vose JM; Solheim JC
Hybridoma (Larchmt); 2006 Oct; 25(5):306-8. PubMed ID: 17044787
[TBL] [Abstract][Full Text] [Related]
18. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
Inogès S; Rodrìguez-Calvillo M; Zabalegui N; Lòpez-Dìaz de Cerio A; Villanueva H; Soria E; Suárez L; Rodríguez-Caballero A; Pastor F; García-Muñóz R; Panizo C; Pèrez-Calvo J; Melero I; Rocha E; Orfao A; Bendandi M; ;
J Natl Cancer Inst; 2006 Sep; 98(18):1292-301. PubMed ID: 16985248
[TBL] [Abstract][Full Text] [Related]
19. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.
Davis TA; Maloney DG; Czerwinski DK; Liles TM; Levy R
Blood; 1998 Aug; 92(4):1184-90. PubMed ID: 9694706
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells.
Maloney DG; Brown S; Czerwinski DK; Liles TM; Hart SM; Miller RA; Levy R
Blood; 1992 Sep; 80(6):1502-10. PubMed ID: 1520877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]